Evidence map›Paper›PMID 28199981›Full record

ArticleOncotarget2017

Growth differentiation factor 15 induces growth and metastasis of human liver cancer stem-like cells via AKT/GSK-3β/β-catenin signaling.

Qiong Xu, Hai-Xu Xu, Jin-Ping Li, Song Wang, Zheng Fu, Jing Jia, Li Wang, Zhi-Feng Zhu, Rong Lu, Zhi Yao

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
6.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 65 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Hepcidin in hepatocellular carcinoma.British journal of cancer · 2022
    Review
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Qiong XuDepartment of Immunology, Tianjin Medical University, Tianjin, China.
Hai-Xu XuDepartment of Immunology, Tianjin Medical University, Tianjin, China.
Jin-Ping LiTianjin Kangzhe Pharmaceutical Company, Ltd., Tianjin, China.
Song WangTianjin Kangzhe Pharmaceutical Company, Ltd., Tianjin, China.
Zheng FuDepartment of Immunology, Tianjin Medical University, Tianjin, China.
Jing JiaTianjin Kangzhe Pharmaceutical Company, Ltd., Tianjin, China.
Li WangDepartment of Immunology, Tianjin Medical University, Tianjin, China.
Zhi-Feng ZhuTianjin Kangzhe Pharmaceutical Company, Ltd., Tianjin, China.
Rong LuDepartment of Immunology, Tianjin Medical University, Tianjin, China.
Zhi YaoDepartment of Immunology, Tianjin Medical University, Tianjin, China.
Tianjin Institute of Pharmaceutical Research (China) · CNTianjin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer stem cells in liver cancer are thought to be responsible for tumor recurrence and metastasis. However, the factors that mediate this mechanism have yet to be completely elucidated. In this study, we isolated CD13+CD44+ sphere cells (SCs) derived from liver cancer tissues and SK-Hep-1 cells, which possessed cancer stem cell-like properties. Through cytokine array analysis, growth differentiation factor 15 (GDF15) was significantly increased in SCs. Clinical data showed GDF15 was overexpressed in liver cancer tissues and was positively related to pathological grading. GDF15 knockdown significantly inhibited the growth and metastasis of SCs through AKT/GSK-3β/β-catenin pathway suppression. Moreover, a PI3K inhibitor LY294002 inhibited AKT/GSK-3β/β-catenin pathway activated by GDF15 and attenuated GDF15-induced proliferation, colony formation and invasion of SCs.

conclusionOur studies suggest that CD13+CD44+ SCs may represent a subset of LCSCs. GDF15 promotes the growth and metastasis of SCs by activating AKT/GSK-3β/β-catenin signaling pathway. Promisingly, GDF15 could be considered as a potential therapeutic target in liver cancer.

Indexed as

Animalsbeta CateninBlotting, WesternCarcinoma, HepatocellularCell Line, TumorCell ProliferationChromonesEnzyme InhibitorsFemaleGlycogen Synthase Kinase 3 betaGrowth Differentiation Factor 15HumansImmunohistochemistryLiver NeoplasmsMaleMice, Inbred NOD2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-onebeta CateninChromonesEnzyme InhibitorsGDF15 protein, humanGlycogen Synthase Kinase 3 betaGrowth Differentiation Factor 15MorpholinesProto-Oncogene Proteins c-aktcancer stem cellsGDF15hepatocellular carcinomametastasistumorigenesis

Identifiers

PMID28199981
PMCPMC5370015
OpenAlexW2588869324

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.